Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 30 | 2023 | 3143 | 3.420 |
Why?
|
Kidney Neoplasms | 28 | 2023 | 4262 | 2.910 |
Why?
|
Pelvis | 9 | 2020 | 730 | 1.690 |
Why?
|
Posture | 6 | 2020 | 958 | 1.100 |
Why?
|
Spine | 5 | 2020 | 1144 | 0.990 |
Why?
|
Gait | 4 | 2020 | 793 | 0.870 |
Why?
|
Neoplasms | 22 | 2023 | 21683 | 0.870 |
Why?
|
Cerebral Palsy | 4 | 2018 | 459 | 0.830 |
Why?
|
Immunotherapy | 11 | 2023 | 4445 | 0.770 |
Why?
|
Scoliosis | 4 | 2020 | 725 | 0.700 |
Why?
|
Imaging, Three-Dimensional | 9 | 2020 | 4042 | 0.680 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2020 | 11524 | 0.640 |
Why?
|
Salvage Therapy | 2 | 2018 | 1275 | 0.600 |
Why?
|
Nephritis, Interstitial | 1 | 2018 | 156 | 0.590 |
Why?
|
Kyphosis | 2 | 2020 | 237 | 0.580 |
Why?
|
Antineoplastic Agents | 8 | 2021 | 13695 | 0.570 |
Why?
|
Down Syndrome | 3 | 2018 | 880 | 0.520 |
Why?
|
Walking | 4 | 2020 | 1180 | 0.520 |
Why?
|
Patient Positioning | 3 | 2018 | 324 | 0.500 |
Why?
|
Purines | 1 | 2018 | 594 | 0.490 |
Why?
|
Aminopyridines | 1 | 2018 | 542 | 0.480 |
Why?
|
Bone and Bones | 2 | 2020 | 2575 | 0.480 |
Why?
|
Physical Fitness | 1 | 2018 | 733 | 0.470 |
Why?
|
Androgen Antagonists | 2 | 2021 | 1377 | 0.430 |
Why?
|
Benzimidazoles | 1 | 2018 | 850 | 0.430 |
Why?
|
Cervical Vertebrae | 2 | 2018 | 975 | 0.410 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2018 | 808 | 0.400 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2018 | 2245 | 0.390 |
Why?
|
Lordosis | 2 | 2018 | 84 | 0.380 |
Why?
|
Pandemics | 10 | 2022 | 8388 | 0.380 |
Why?
|
Pyridines | 3 | 2020 | 2825 | 0.370 |
Why?
|
Lymphatic Diseases | 1 | 2022 | 324 | 0.370 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 252 | 0.360 |
Why?
|
Therapies, Investigational | 1 | 2021 | 112 | 0.360 |
Why?
|
Humans | 92 | 2023 | 744343 | 0.350 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 315 | 0.350 |
Why?
|
Peritoneal Dialysis | 1 | 2020 | 146 | 0.340 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 104 | 0.330 |
Why?
|
Radiography | 6 | 2020 | 7023 | 0.330 |
Why?
|
Early Detection of Cancer | 3 | 2021 | 3086 | 0.320 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3133 | 0.320 |
Why?
|
Crohn Disease | 2 | 2019 | 2303 | 0.310 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3240 | 0.310 |
Why?
|
Spinal Curvatures | 1 | 2018 | 66 | 0.310 |
Why?
|
Acetabulum | 2 | 2020 | 525 | 0.310 |
Why?
|
Femur | 2 | 2018 | 1297 | 0.310 |
Why?
|
Piperazines | 1 | 2018 | 2488 | 0.300 |
Why?
|
Thigh | 1 | 2018 | 247 | 0.300 |
Why?
|
Immunologic Factors | 3 | 2021 | 1580 | 0.300 |
Why?
|
Interleukin-8 | 1 | 2020 | 690 | 0.290 |
Why?
|
Fixation, Ocular | 1 | 2018 | 251 | 0.290 |
Why?
|
Foot Deformities | 1 | 2016 | 36 | 0.290 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2019 | 841 | 0.280 |
Why?
|
Lebanon | 5 | 2019 | 229 | 0.280 |
Why?
|
Pelvic Bones | 1 | 2017 | 265 | 0.260 |
Why?
|
Postural Balance | 1 | 2020 | 620 | 0.260 |
Why?
|
Spinal Cord Diseases | 1 | 2018 | 298 | 0.260 |
Why?
|
Lower Extremity | 3 | 2020 | 1158 | 0.260 |
Why?
|
Healthcare Disparities | 3 | 2021 | 3158 | 0.260 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2023 | 3508 | 0.250 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2734 | 0.250 |
Why?
|
Algorithms | 2 | 2021 | 13881 | 0.250 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3586 | 0.250 |
Why?
|
Tomography, Spiral Computed | 1 | 2016 | 280 | 0.250 |
Why?
|
Joints | 1 | 2016 | 326 | 0.250 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2022 | 4479 | 0.240 |
Why?
|
Body Mass Index | 3 | 2021 | 12720 | 0.240 |
Why?
|
Gait Disorders, Neurologic | 1 | 2016 | 231 | 0.240 |
Why?
|
Thoracic Vertebrae | 1 | 2018 | 608 | 0.240 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1581 | 0.230 |
Why?
|
Urban Population | 1 | 2022 | 2021 | 0.230 |
Why?
|
Male | 43 | 2023 | 350118 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2022 | 8428 | 0.220 |
Why?
|
Young Adult | 18 | 2020 | 56430 | 0.220 |
Why?
|
Infection Control | 1 | 2020 | 966 | 0.220 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2017 | 1184 | 0.220 |
Why?
|
Retreatment | 2 | 2020 | 610 | 0.210 |
Why?
|
Joint Diseases | 1 | 2016 | 480 | 0.200 |
Why?
|
Female | 40 | 2023 | 380194 | 0.200 |
Why?
|
Homosexuality, Male | 1 | 2019 | 1240 | 0.200 |
Why?
|
Upper Extremity | 1 | 2016 | 648 | 0.200 |
Why?
|
Rural Population | 1 | 2022 | 2210 | 0.200 |
Why?
|
Tomography, X-Ray Computed | 7 | 2022 | 20129 | 0.190 |
Why?
|
Prostatic Neoplasms | 3 | 2021 | 11124 | 0.190 |
Why?
|
Aged | 25 | 2023 | 163280 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9239 | 0.190 |
Why?
|
Retrospective Studies | 19 | 2023 | 77449 | 0.180 |
Why?
|
Nephrectomy | 3 | 2022 | 1050 | 0.180 |
Why?
|
Anilides | 2 | 2020 | 408 | 0.180 |
Why?
|
Middle Aged | 25 | 2023 | 213383 | 0.180 |
Why?
|
Survival Analysis | 4 | 2021 | 10252 | 0.180 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 7913 | 0.180 |
Why?
|
Protein Kinase Inhibitors | 4 | 2022 | 5535 | 0.180 |
Why?
|
Cross-Sectional Studies | 9 | 2020 | 25043 | 0.180 |
Why?
|
Sexual Behavior | 1 | 2019 | 2057 | 0.180 |
Why?
|
Range of Motion, Articular | 1 | 2016 | 1578 | 0.180 |
Why?
|
Adult | 24 | 2022 | 214055 | 0.170 |
Why?
|
Functional Laterality | 1 | 2016 | 2290 | 0.170 |
Why?
|
Movement | 1 | 2016 | 1471 | 0.170 |
Why?
|
Hip Joint | 1 | 2016 | 1002 | 0.170 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 212 | 0.170 |
Why?
|
Parenteral Nutrition, Total | 1 | 2019 | 302 | 0.160 |
Why?
|
Outpatients | 1 | 2016 | 1486 | 0.160 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7722 | 0.160 |
Why?
|
Sarcoma | 1 | 2019 | 1897 | 0.160 |
Why?
|
Adolescent | 14 | 2020 | 85781 | 0.150 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2538 | 0.150 |
Why?
|
Medical Oncology | 3 | 2022 | 2265 | 0.150 |
Why?
|
Enterobacteriaceae Infections | 1 | 2019 | 187 | 0.140 |
Why?
|
Cohort Studies | 7 | 2023 | 40561 | 0.140 |
Why?
|
Aged, 80 and over | 13 | 2021 | 57776 | 0.140 |
Why?
|
Femur Neck | 1 | 2018 | 309 | 0.140 |
Why?
|
Liver Failure | 1 | 2018 | 241 | 0.140 |
Why?
|
Biomedical Research | 1 | 2022 | 3309 | 0.140 |
Why?
|
DNA Methylation | 1 | 2020 | 4286 | 0.140 |
Why?
|
Muscle, Skeletal | 2 | 2018 | 4931 | 0.140 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 8642 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 322 | 0.130 |
Why?
|
Carrier State | 1 | 2019 | 518 | 0.130 |
Why?
|
Multiple Organ Failure | 2 | 2023 | 390 | 0.130 |
Why?
|
Platelet Count | 1 | 2017 | 781 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 538 | 0.120 |
Why?
|
Databases, Genetic | 1 | 2021 | 1783 | 0.120 |
Why?
|
Melanoma | 1 | 2023 | 5510 | 0.120 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9274 | 0.120 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2020 | 290 | 0.120 |
Why?
|
Taxoids | 1 | 2017 | 666 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 9959 | 0.120 |
Why?
|
Drug Utilization | 1 | 2020 | 1183 | 0.120 |
Why?
|
Palliative Care | 2 | 2019 | 3493 | 0.120 |
Why?
|
Anthropometry | 1 | 2018 | 1350 | 0.120 |
Why?
|
Leukocyte Count | 1 | 2017 | 1588 | 0.110 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4258 | 0.110 |
Why?
|
Computer Simulation | 1 | 2016 | 6196 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2019 | 1530 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2018 | 804 | 0.110 |
Why?
|
Severity of Illness Index | 4 | 2022 | 15540 | 0.110 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.110 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.100 |
Why?
|
Methotrexate | 1 | 2019 | 1727 | 0.100 |
Why?
|
Tennessee | 1 | 2021 | 117 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2018 | 2455 | 0.100 |
Why?
|
Oxygen Consumption | 1 | 2018 | 1869 | 0.100 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11031 | 0.100 |
Why?
|
Neutrophils | 2 | 2020 | 3719 | 0.100 |
Why?
|
Health Facilities | 2 | 2022 | 573 | 0.100 |
Why?
|
Pyrroles | 1 | 2018 | 1146 | 0.100 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13102 | 0.100 |
Why?
|
Genomics | 4 | 2022 | 5720 | 0.100 |
Why?
|
Angiotensin I | 1 | 2021 | 57 | 0.100 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1038 | 0.090 |
Why?
|
Censuses | 1 | 2022 | 200 | 0.090 |
Why?
|
Reproducibility of Results | 5 | 2020 | 19905 | 0.090 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 35 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5221 | 0.090 |
Why?
|
Breast Neoplasms | 1 | 2018 | 20822 | 0.090 |
Why?
|
Risk Factors | 6 | 2022 | 72290 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2017 | 4851 | 0.090 |
Why?
|
Cause of Death | 3 | 2022 | 3584 | 0.090 |
Why?
|
Respiratory Insufficiency | 1 | 2018 | 1199 | 0.090 |
Why?
|
Joint Instability | 2 | 2018 | 792 | 0.090 |
Why?
|
Reference Values | 2 | 2017 | 4982 | 0.090 |
Why?
|
Indoles | 1 | 2018 | 1839 | 0.090 |
Why?
|
Cell Cycle | 1 | 2018 | 2967 | 0.090 |
Why?
|
Postoperative Period | 2 | 2019 | 1842 | 0.090 |
Why?
|
Cross Infection | 1 | 2019 | 1416 | 0.090 |
Why?
|
Lymphocytes | 1 | 2017 | 2617 | 0.090 |
Why?
|
Pyrimidines | 2 | 2018 | 2942 | 0.080 |
Why?
|
Telemedicine | 2 | 2020 | 2872 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2017 | 21746 | 0.080 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2021 | 365 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1671 | 0.080 |
Why?
|
Mutation | 3 | 2021 | 29786 | 0.080 |
Why?
|
Gene Fusion | 1 | 2022 | 371 | 0.080 |
Why?
|
Drugs, Investigational | 1 | 2021 | 214 | 0.080 |
Why?
|
Survival Rate | 3 | 2020 | 12788 | 0.080 |
Why?
|
Ligases | 1 | 2020 | 333 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 552 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6459 | 0.080 |
Why?
|
Anatomy, Comparative | 1 | 2017 | 4 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2214 | 0.080 |
Why?
|
Calcaneus | 1 | 2020 | 138 | 0.080 |
Why?
|
Sulfonamides | 1 | 2018 | 1938 | 0.080 |
Why?
|
Angiotensin II | 1 | 2021 | 881 | 0.080 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2021 | 449 | 0.080 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 253 | 0.080 |
Why?
|
Condoms | 1 | 2019 | 323 | 0.070 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 759 | 0.070 |
Why?
|
Syphilis | 1 | 2019 | 227 | 0.070 |
Why?
|
Brain Neoplasms | 1 | 2018 | 8863 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2023 | 2649 | 0.070 |
Why?
|
Foot Joints | 1 | 2016 | 36 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2214 | 0.070 |
Why?
|
Treatment Outcome | 6 | 2020 | 63114 | 0.070 |
Why?
|
Hydroxychloroquine | 2 | 2020 | 412 | 0.070 |
Why?
|
DNA-Binding Proteins | 3 | 2021 | 9648 | 0.070 |
Why?
|
Foot | 1 | 2020 | 527 | 0.070 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 713 | 0.070 |
Why?
|
Students, Medical | 1 | 2019 | 1862 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2018 | 3528 | 0.070 |
Why?
|
Bone Density | 1 | 2018 | 3468 | 0.070 |
Why?
|
Rotation | 1 | 2017 | 523 | 0.060 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1097 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1518 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6489 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12245 | 0.060 |
Why?
|
Prospective Studies | 5 | 2022 | 53288 | 0.060 |
Why?
|
Receptors, Androgen | 1 | 2021 | 1058 | 0.060 |
Why?
|
DNA Helicases | 1 | 2020 | 859 | 0.060 |
Why?
|
Biopsy | 2 | 2021 | 6756 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3597 | 0.060 |
Why?
|
Transcription Factors | 3 | 2021 | 12208 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12261 | 0.060 |
Why?
|
Organ Size | 1 | 2018 | 2252 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4253 | 0.060 |
Why?
|
HIV Infections | 1 | 2019 | 16718 | 0.060 |
Why?
|
Colonoscopy | 1 | 2021 | 1367 | 0.060 |
Why?
|
International Cooperation | 1 | 2019 | 1420 | 0.050 |
Why?
|
Prognosis | 4 | 2020 | 29063 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 142 | 0.050 |
Why?
|
Accidental Falls | 1 | 2020 | 1062 | 0.050 |
Why?
|
Child | 5 | 2018 | 77709 | 0.050 |
Why?
|
Electromyography | 1 | 2016 | 1379 | 0.050 |
Why?
|
Prostate-Specific Antigen | 1 | 2021 | 2494 | 0.050 |
Why?
|
Observer Variation | 1 | 2017 | 2593 | 0.050 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2569 | 0.050 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1861 | 0.050 |
Why?
|
Databases, Factual | 2 | 2020 | 7729 | 0.050 |
Why?
|
Georgia | 1 | 2020 | 186 | 0.050 |
Why?
|
Diet | 1 | 2018 | 7939 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2019 | 3479 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 2849 | 0.050 |
Why?
|
Mammography | 1 | 2021 | 2476 | 0.040 |
Why?
|
Forecasting | 1 | 2019 | 2951 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2018 | 6365 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2021 | 528 | 0.040 |
Why?
|
Odds Ratio | 1 | 2022 | 9849 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 380 | 0.040 |
Why?
|
Middle East | 1 | 2019 | 219 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 196 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 631 | 0.040 |
Why?
|
Diaphyses | 1 | 2018 | 65 | 0.040 |
Why?
|
Preceptorship | 1 | 2019 | 61 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 275 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2022 | 3679 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2020 | 535 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2021 | 5097 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 572 | 0.040 |
Why?
|
Massachusetts | 1 | 2021 | 8663 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 705 | 0.040 |
Why?
|
Histone Demethylases | 1 | 2020 | 321 | 0.040 |
Why?
|
Indazoles | 1 | 2018 | 289 | 0.030 |
Why?
|
Macrophages | 1 | 2021 | 5655 | 0.030 |
Why?
|
Femur Head | 1 | 2018 | 301 | 0.030 |
Why?
|
Registries | 1 | 2022 | 8089 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5172 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 890 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11366 | 0.030 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2020 | 670 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2505 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1475 | 0.030 |
Why?
|
Mass Screening | 1 | 2021 | 5255 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2020 | 1401 | 0.030 |
Why?
|
Quality Improvement | 1 | 2020 | 3749 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 987 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5853 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2018 | 424 | 0.030 |
Why?
|
Heart Failure | 1 | 2018 | 10900 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1025 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2020 | 1284 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1142 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1677 | 0.030 |
Why?
|
Time Factors | 3 | 2020 | 40075 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 3327 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2020 | 4468 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 857 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1338 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2021 | 1041 | 0.030 |
Why?
|
Universities | 1 | 2019 | 956 | 0.030 |
Why?
|
Prevalence | 1 | 2019 | 15226 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2751 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2012 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2020 | 2107 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2109 | 0.020 |
Why?
|
Androgens | 1 | 2017 | 1281 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 2038 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3278 | 0.020 |
Why?
|
United States | 2 | 2022 | 69872 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39050 | 0.020 |
Why?
|
Animals | 2 | 2021 | 168757 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6538 | 0.020 |
Why?
|
Quality of Life | 1 | 2019 | 12804 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 2987 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4420 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2018 | 6895 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8340 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.020 |
Why?
|
Hemorrhage | 1 | 2018 | 3461 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2020 | 5317 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10397 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10388 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6770 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7785 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9438 | 0.020 |
Why?
|
Kidney | 1 | 2019 | 7186 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18370 | 0.010 |
Why?
|
Risk Assessment | 1 | 2021 | 23338 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23403 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2018 | 11727 | 0.010 |
Why?
|